NCT00322608View on ClinicalTrials.gov

Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2009

Conditions
Cancer
Interventions
DRUG

NPI-2358

Treatment on Days 1, 8 and 15 in a 28 day cycle

Trial Locations (3)

48201

Barbara Ann Karmanos Cancer Institute/Wayne State University, Detroit

98405

Northwest Medical Specialties, Tacoma

78245-3217

Institute for Drug Development, San Antonio

Sponsors
All Listed Sponsors
lead

Nereus Pharmaceuticals, Inc.

INDUSTRY

NCT00322608 - Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter